Enveda Raises $311 Million for AI Drug Discovery
Enveda raised a $311 million Series E at a $2 billion valuation to advance drugs discovered from plants and microbes into clinical trials.
Enveda is revolutionizing drug discovery by leveraging a platform that deciphers nature's complex chemistry at unprecedented speed and scale. By harnessing the vast, untapped potential of natural molecules, Enveda aims to accelerate the development of new medicines, achieving results four times faster than the industry average. The company aspires to transform the unknown elements of the natural world into accessible insights for drug hunters, thus offering hope for better treatments. Enveda's mission is supported by a dedicated team focused on curiosity and innovation, striving to unlock the chemical code of nature for global health advancements.
Daily report covering major AI developments and industry news, with both top stories and complete market updates